Daily Cosmetic Research Analysis

The encapsulation of lipophilic compounds for use in the cosmetic, food, and detergency industries is an area of growing interest. However, most current strategies rely on non-biodegradable materials, often classified as microplastics, which pose significant environmental risks. To address these issues, alternative encapsulation methods using biodegradable materials are being developed. Despite their potential, these methods have yet to demonstrate efficacy or economic feasibility comparable to conventional encapsulation systems. To overcome these challenges, a novel strategy has been developed for the encapsulation of lipophilic compounds, such as fragrances, using sodium alginate (SA). This approach involves the formation of an oil-in-water nanoemulsion via the Phase Inversion Composition method, with polysorbate 80 serving as the surfactant. The process is followed by the internal gelation of SA and subsequent dispersion to generate the final microcapsules. The formulation was optimized by varying the ratios of surfactant, oil, and aqueous phases in the nanoemulsion. Characterization techniques, including Dynamic Light Scattering, Gas Chromatography-Mass Spectrometry, and Thermogravimetric Analysis, confirmed successful encapsulation (average of 81 %, up to 97 % for one fragrance). The formulations demonstrated prolonged release profiles, with the scent remaining detectable for up to 30 days. An organoleptic study further revealed that encapsulated fragrances retained higher perceived intensity over time compared to their non-encapsulated counterparts. Moreover, the microcapsules exhibited excellent long-term stability within a conditioner matrix, maintaining their fragrance load for four months. This work represents a significant advancement in the development of environmentally friendly encapsulation methods for lipophilic compounds, offering promising applications in the cosmetic industry.

New Approach Methodologies (NAMs) are gaining significant momentum globally to reduce animal testing and enhance the efficiency and human relevance of chemical safety assessment. Even with substantial EU commitment from regulatory agencies and the academic community, the full regulatory adoption of NAMs remains a distant prospect. This challenge is further complicated by the fact that the academic world, oriented toward NAMs development, and regulatory agencies, focused on practical application, frequently operate in separate spheres. Addressing this disconnect, the present paper, developed within the European Partnership for the Assessment of Risks from Chemicals (PARC), provides a clear overview of both the available non-animal tests and current evaluation practices for genotoxic and carcinogenic hazard assessment, while simultaneously highlighting existing regulatory needs, gaps, and challenges toward greater human health protection and the replacement of animal testing through NAMs adoption. The analysis reveals a complex landscape: while the EU is deeply committed to developing and adopting NAMs, as outlined in its Chemical Strategy for Sustainability and supported by initiatives like PARC, prescriptive regulations such as Classification, Labelling and Packaging (CLP) and Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) still heavily mandate in vivo animal data for hazard classification, particularly for germ cell mutagenicity and carcinogenicity. This reliance creates a "too-short-blanket-problem," where efforts to reduce animal testing may impact human health protection because of the current in vivo-based classification criteria. In contrast, sectors such as cosmetics and certain European Food Safety Authority (EFSA)-regulated products demonstrate greater flexibility toward progressive integration of NAMs. While the deep mechanistic understanding of genotoxicity and carcinogenicity has significantly advanced the integration of alternatives to animal tests into regulatory chemical hazard assessment, their broader and full implementation faces considerable challenges due to both scientific complexities (i.e., the development and validation of fit-for-purpose NAMs) and existing legislative provisions.

Ethical concerns, high costs, and scientific limitations associated with animal testing have accelerated the search for alternative methods to evaluate the safety and efficacy of topical cosmetic formulations. This study provides a comprehensive analysis of the global patent landscape related to non-animal testing approaches for skin care products, focusing on filings from January 2015 to March 2025, indexed in the Espacenet database. From 470 patent applications initially screened, 23 met the predefined inclusion and exclusion criteria and were selected for in-depth analysis. Key innovations include 3D epidermal models featuring melanocytes, hair follicles, and sebaceous glands; advanced microfluidic chips, and enzyme-based chemical toxicity assays. Although supported by regulatory frameworks, challenges persist regarding standardization, reproducibility, and the ethical sourcing of human tissue. This patent application review reveals a clear shift toward advanced 3D models and organ-on-a-chip technologies that better replicate the complexity of human skin physiology. The trends observed indicate that alternative methods to animal testing are not only an ethical necessity but are also becoming a technological reality, offering more predictive, reliable, and efficient strategies for safety assessment.